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We have iavcstil~tCd the involveraent of protein-tyrosin¢ kinases in throrabia.induced agMe~ttion of human platelets, usinii ST638 and Ilenittein 
which are known inhibitors ofprotein.tyrosine kinas¢ Preineubation of platelcti with S0/,tM of S'l'fi3~ or 2S #glt-nl ofgenistein completely blocked 
the platelet aure~tion indur~d with 0,0S unit/ml of throrabin. The increa~ of protein.tyrosinc phosphorylation bands (135.. 124.. 71b, 64., and 
60.kDa) induead with throrabln was also inhibited by these inhibitori n a dote-dependent raanncr, There inhibitors also blocked the plastics 
alflircBation and protcin-tyrosine phosphowlation induced with throrabin in aspirin.treated platdet,~, Incrca~ or tile intraccllular Ca:" concentra- 
tion induced by throrabin was lso inhibited by higher con~ntrations of genistein. Th¢~ results uue~t that tile protein-tyrosin¢ phosphorylntion 
plays a ~rtain role in platdet activation having som~ rdation to the intra~llular Ca-" concentration, 
Platclet allgregatiom Throrabin; Protein.tyrosine phosphowlation; Ca~'; ST638; G¢nistein 
I, INTRODUCTION 
Stimulation of human platelets by physiological g- 
onists uch as thrombin and collagen is associated with 
a rapid turnover of inositol pho~pholipids through 
phosph,Aipase C activation, which leads to intramem- 
brane diacylglycerol (DIS) and inositol 1,4,5-tri- 
phosphate ips) [1-3]. These DO and IP~, which activate 
protein kinase C and mobilization of intra~llular Ca 2". 
respectively, are considered to be intracellular messen- 
gers [4,5]. Thus, physiological r¢spons~ of platelets are 
elicited concurrently with these putative signal 
transduction pro~sses. Though high levels of protein- 
tyrosine kinas¢ activity have been found in some non- 
proliferating terminally differentiated cells such as neu- 
rons and platelets [6-8], the physiological function of 
protein-tyrosine kinases and their regulatory mecha- 
nism in normal ~ lh  have not b~n clearly understood. 
Platelets possa.~s s~veral protcin-tyrosine kinases such 
as the cellular src gone crfyn gene products [8-10] and 
unidentified kinases It l], In plat¢lets, pp60 ` ''~ is partic- 
ularly rich [8]. 
Prot¢in-tyrosine phosphorylation is transiently ele- 
vated in intact human platelets when it is stimulated 
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with various agonists [12-18]. Cellular responses of 
platelets, i.e. aggregation and dense granule secretion, 
are also tightly correlated with the protein-tyrosine 
phosphorylation [13,14]. On the other hand. it has b~n 
recently found that the potent and specific protein-t,vro- 
sine kinase inhibitors suclx as erbstatin or genistein 
block the platelet activating factor (PAF)-induced plate- 
let activation in rabbit [19,20]. In this paper, we will 
report the involvement of protein-tyrosine kinases in 
thrombin-induced aggregation i  human platelets, with 
use of ST638 (~-cyano-3.ethoxy-4-hydroxy-5-phenyl- 
thiomethylcinnamamid¢) and genistcin. 
2. EXPERIMENTAL 
2,1, Materials tad chen~ieala 
Human thrombin, prostaglandin El and apyrase were purchased 
from Sigraa, Gcnistcin a d daid~in were obtained from Funakoshi 
Pharmaceutical Co, ST638 was a generous gilt from Dr, Tadayoshi 
Shiraishi, Biocheraical Research Laboratories, Kanegafuchi Chemical 
Industry Co., Ltd, Other chcraicals were reagent grad=. Antibodies 
against phosphotyroslnc conjugated to human iraraunoglolaulin were 
prepared by the method of EK and Heldin [211. 
2,2, Methods 
Isolation of human platelets and anti.phosphotyrosine iramunoblot 
anal~is were carried out us descril~d previously [161, Platclet agBrcga- 
tion was monitored using Chronolog Laraiaggregoraeter (CHRONO- 
LOG. Corp,) as described prcvio~ly [16], 
For the raeasufera~nt of protein-tyrosinc kinase activity in theplate- 
lets extracts in vitro, washed platelets were suspended in 10 vols. of 
butter (50 mM Tri.~.HCI, pH 7,5, 1 rnM EDTA, 10 raM 2-raercap 
tocthanol and 10% 81ycerol). The suspension was sonieated in anice
bath with three 15 s bursts in a sonieator, Particulate material was 
collected by centrifugation at 100,000 x g for 60 rain at 4"C and 
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mlubilbmd in th~ buffer containing 0,5~ Triton X-100. The activiti¢~ 
of particulate I'ractions were then astmye.d by n'w.nsurinil th~ phospho- 
o, lation of E**G, (EDAEYAARRRG) as d~¢ril~..d previoutly ['/], in 
the prci*nc¢ el" various concentrations of" prot,i,~-tyrosir~ kinatm in. 
Mbitors, for 5 thin at 30"C. 
For the measurement of tntra~llular Ca:" conccnt~tion, plat¢lets 
(1 rot, ~-$ x 10 ~ ¢¢lldml) w, re placed on c~v<tt~ at 37"C with stirring, 
and fiuore~en¢¢ was monitored in a Shimadzu fluoremm¢, spectre. 
mct~r RF.50~O with standard monitor setting of 340 mad 380 nm 
~xcitation and 490 nm cmi~ion, Plat¢l¢ts w~rc loaded with Fura2-AM 
at a final con¢cntnttion f 5 pM for ~0 min at 3"/*C and wasl~¢d with 
HEPF..S.buffer©d saline. Washed platelets w,r¢ preineubatcd for 2 rain 
in the ubscnc~ or prcmnce ofgenistein and stimulated by thrombin and 
the a~l~is continued for 3 min, in the preaanc¢ of ST6atS wc could 
not measure the intraccl|ulur Ca"' con¢cntration btttmu~R o£ havinll 
fluo.-c,~nce it,,elf, 
3. RESULTS 
In the previous articles [14,16-! 8] we have shown that 
protein-tyrosine phosphorylation of several proteins is 
enhanced by the treatment of agonisty such as throm- 
bin, collagen, calcium ionophore A23187, vanadat¢ 
with H.O.. and wheat germ agglutinin in human plate- 
lets. We have chosen ST638 and genistein which have 
distinct inhibitory mechanisms of action to protein.ty. 
rosine kintv~es to investigate whether protein-tyrosine 
kinases arc required for the platelct aggregation i duced 
with thrombin in human platelets. Fig. I shows a dosc- 
r~sponse for ST638 or genistein inhibition of platelet 
aggregation i duced with thrombin at a concentration 
of 0.05 unirdml. Thrombin.induced aggregation was 
blocked by these inhibitors in a dose.dependent man- 
ner, The concentration of ST638 or gcni~t~in which 
A) B) ¢Qnt, 
~ t  C~nt' 
~,~ 
l a~n 
Fill. I. Effects of ST63tl or ~nistcin on platclct aurc~tion indu~zd 
with thrombin in intact human plat¢lets. Plztelet, w~re preincubat~ 
for 2 rain in the pmmno: of indicat~ oanccnt~tion of (A) s'r63~ 
(O-SO/aM) (B) gcnist¢in (O-2S/aWml) before the stimulztion bythrom. 
bin (0.05 unWmi). Then agip'c~tion wzz-. measurer as dcrcribcd in 
~¢tion 2. The arrow indicated the addition of thrombin. Cont, " in 
the ab~mm of inhibitors. 
inhibited platclet aggregation to the basal level was 50 
/aM or 25 .ug/ml, resp¢ctively. 
In the n~t experiments we examined the inhibitory 
effect for the protein.tyrosine phosphorylation in plate- 
lets induced by thrombin at a concentration of 0.05 
unit/ml with the treatment of ST638 or genistein by 
W~tern blotting using anti-phosphotyrosinc antibod- 
ies. As shown in Fig, 2, fi,~c phosphotyrosin¢ protein 
bands (135-, 124-0 76-, 64- and 60okDa) which were 
stimulated by thrombin were redu~d by the addition of 
ST638 or genistein. This inhibitory effect wa.t ¢.orr¢lat~d 
with that of platelet aggregation. 
A) s) 
Cont. Tlarombin 
I I 
0 50 2512.5 gT( M) 0 
Cont. Thrombin 
I I 
0 25 12.56.25 Ge( g/ml) ._0 
76K 
54K 
5OK 
FiB, 2, Inhibition of ST638 or genitt¢in on thrombin.lndu~'..d protein-wreathe phospho~lation byimmunoblottin$. Flatel~s were stimulat~ by 
thrombin (0,05 unit/ml) for 2 rain after 2 rain preincubation i  the pre~n~ of the indicated conccntra!icn of (A) ST638 or (B) ~nist¢in. Sampl~ 
were subj¢ct~-d to SD~-I0% polyacrylamid~ gel ~l~trophoresis, transl'errcd to polyvinyliden difluoride membrane, probed with antiphosphoty- 
cosine anti.~rum as dcr, cribcd previously [16], ST. ST638 (/aM); G*', geni~tcin g/ml); Cont, = no stimtdation by thrombin, The lln~ indicate the 
positions of proteins with molecular mas:~¢~ of 135-, 12A., 75-, 64., and 60.kDa that und0rwent tyrosln~ pho~phorylation n rcspon~ to thrombin 
,~timulation, 
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Concentration of Inhibitor= 
Fi~, 3, EITccts of $T6)t~ or 8enistein on tl;c protein.tyro=the kina~ 
activity in the human platelet extracts in vitro, l~rtiealate fractions 
of platclet ¢xlracts were assayed ['or protein.,yrosin¢ kinnsc activity 
by measuring the phosphorylation o[' E.G, as a s.bs|r'atc, The kina~ 
ac|ivitics were as~yed in the pr~n¢¢ of(A) ST63~ (0-1001tM) and 
(B) gent=rein (0-100pll/ml) as described in ~ction 2. Th¢,,,~ resulls were 
rcpre~ntath,c of tllrce experiments, 
Although ST638 and genist¢in have be¢n known po- 
tent and specific inhibitors for protein-tyrosin¢ kinases, 
it is nec¢ssary to examine whether activities of protein- 
tyrosine kinases in plat=let extracts were inhibited by 
them, We assayed protein.tyrosine kinase activity by 
measuring the tyrosine phosphorylation f E**G, which 
is one of the best sabstratcs for protein-tyro=in= kinasss. 
Fig, 3 shows effects of ST638 or gent=rein on protein- 
tyrosinc kinase activiti~ in human platelet particulate 
fractions in vitro, The kina~ activities of particulate 
fraction from platelet extracts were much higher than 
tho~ of supernatant fractions (data not shown). Both 
inhibitor= strongly inhibited the protein-tyrosin¢ kinas¢ 
activities from human platclets, Halt" maximal inhib- 
itory concentrations f $'1"638 or gen~tein were about 
15 9M or 45/~ml,  r~spectively. 
Recently it has b~n reported that the inhibitory ef- 
fect of genistein on plat=let activation is due to its pre- 
ventive action on thromboxane A2 binding to the recep- 
tor. rather than via inhibition of protein.tyrosin¢ phos- 
phorylation [22], In order to assess whether inhibition 
of ST638 or genistein is related to inhibition of protein- 
tyrosin¢ kinase, these inhibitors and another isoflavone 
compound, aidzcin which has no inhibitory activity for 
proteia.tyrosine kinase [23] but inhibits thromboxane 
A2 binding anf thromboxane A2-induc~ platelet ag- 
gregation [22], were examined for aspirin.treated plate- 
let responses. As shown in Fig, 4, in the presence of 1 
mM aspirin protein-tyrosine phosphorylation induced 
A) 
b c ¢1 
B) co.t.  b ° . 
FIB, 4, Effects ofdaldzein, genistein, or ST63tl on a~plrm-treated plat=let aB~reBation and protein-tyro=the phosphorylation stimulated by thrombin, 
The aspirinized.platelets which were treated with 1 mM aspirin for 30 rain were preincubated without or with asents for 2 rain at 37"C with stirrin~ 
and then stimulated by thrombin (0,06 uniUrnl, a-d), Aliquot= of samples were subjected to $D$-7.5% polyacP/lamide g0i ¢lectrophoresis as 
described previously [16], (A) Piatelet a~greBation and (B) protcin-tyrosinc phosphorylation, a, no asents; b, daldz¢in (50 #B/roll; ¢, $¢nist¢in (50 
/Jg/ml); d, ST638 (50pM); Cont, = no stimulation by thrombin. The arrow indicates |he addition of'thrombin (A), The lines indicate the positions 
o1" proteins with molecular masses o[. 135., 124., and 60.kDa that underwt'nt tyro=in= phosphorylation in response to thrombin stimulation (B), 
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with thrombin at low concentration was observed in 
I35-, 124-, 76-, 64-, and 60-kDa proteins, although two 
phosphotyrosine protein bands of 76-, and 64-kDa in- 
creased slightly. Although SO/aM ST638 and 50/dWml 
genistein inhibited the platelet aggregation and protein- 
tyrosine phosphorylation induced by thrombin in aspi- 
rin-treated platelets, daidzein (50/ag/ml) could inhibit 
neither the platelet aggregation or protein.tyrosin¢ 
phosphorylation. These results uggested that the inhib- 
itory effects of ST638 and genistein on thrombin.in- 
duced platelet activation were not simply due to the 
prevention of its binding to the thromboxane A2 recep- 
tor, bat rather due to the inhibition ofprotein-tyrosine 
kinases. 
In the last experiment we questioned whether these 
inhibitors could inhibit the increase of cellular Ca-" 
when the cells were stimulated by thrombin. As shown 
in Fig. 5 intraccllular Ca'* induced by thrombin was 
inhibited by the addition of genistein in a dose.depend. 
ent manner although a much higher concentration is 
necessary for complete inhibition, The result suggests 
that protein-tyrosin¢ phosphorylation i platelets by 
thrombin may have some relation to the intraceliular 
Ca-" concentration, 
4. DISCUSSION 
It has been known that ST638, which is competitive 
with substrate protein for the protein-tyrosine kinas¢ 
binding site, is a potent and specific inhibitor of protein. 
tyrosine kinases of oncogene and protooncogene prod- 
ucts and epidermal growth factor (EGF} receptor ki- 
nase in vitro [24] or in intact cells [25]. Genistein also 
specifically inhibits the activities of oncogene product 
kinases and EGF receptor kinase, and its inhibitory 
effect is caused by competing with ATP [23]. Both inhib. 
itors did not inhibit the enzyme activities of serine/thre- 
onine-specific protein kinase such as cAMP-dependent 
protein kinase and protein kinase C [23.24]. 
In the present study, we found that ST638 and gen- 
ist¢in inhibited human platelet aggregation, when plate- 
lets were induced with thrombin at a concentration f
0.05 unit/tal. In our ¢~periments, changes of phosphoty. 
rosine protein bands of 135-, 124-, 76-, 4,-, and 60-kDa 
were also bserved by the stimulation with the same 
concentration of thrombin, and tl-',.~ protein-tyrosine 
phosphorylations were reduced to basal level by the 
pretreatment of ST638 or genistein. These inhibitory 
effects were closely correlated with that of platelet ag- 
gregation in a dose-dependent manner. Both inhibitors 
also strongly suppressed the protein-tyrosine kinase ac- 
tivities from the particulate fraction in human platelets 
in vitro. The half-maximal inhibitory concentration of
ST~-;3~ toward protein-tyrosine kinase in vitro was 
about 15/.tM which was almost equivalent to its inhib- 
itory concentration on platelet aggregation. On the 
other hand genistein inhibited its activity at half-maxi- 
a • - .  200  
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Fig. $, Effect of tlenistein on thrombin.induce.d Ca"" mobilization. 
Fura2.AM loaded pl~t¢let', were pr¢incubated (a) withottt or with 
tlenistein (b) 2S p'~'mt, (c) SO g~/ml, and (d) 10O #B/rnl for 2 rain at 
]7"C with .ttirrintl. Intraccllular fl.or~,.,c~nc~ was monitored by glow 
¢ytometry. and after ba~lin¢ 30 ,~-pcriod. thrombin (0.05 uniVml) was 
added (arrow). Detailed conditions are d=~ribed in f.~tion 2. 
real inhibitory con~ntration of about 45 ~ml ,  al- 
though it inhibited platelet aggregation at the con~n- 
tration of 25 .ug/ml. These different inhibitory effects 
may be explained by the dilTerence of inhibitory actions 
between ST638 and genistein. In aspirin.treated plate- 
lets, both ST638 and genistein inhibited the thrombin- 
induced platelet aggregation and protein-tyrosine phos- 
phorylation, whereas daidzein, which has no inhibitory 
activity Ibr protein-tyrosine kinas¢ but inhibits 
['~H]U46619 binding and thromboxane A2-induced 
platelet aggregation [22] did not prevent hrombin-in- 
duced platelet aggregation and protein-tyrosin¢ phos- 
phorylation. These results suggested that the role of 
ST638 and genistein in thrombin-induced platelet ag- 
gregation was at least in part the inhibition of the activ- 
ity of protein-tyrosine kinases. Based on these observa- 
tions, it has been shown that the activation of protein- 
tyrosine kinase may be necessary for platelet aggrega- 
tion stimulated with thrombin in human platdets. 
Therefore, it turns out that protein-tyrosine phospho- 
rylation plays a certain role in human platelet aggrega- 
tion having some relation to the intracellular Ca"* con- 
centration (Fig. 5). 
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It is well known that the thrombin is the most potent 
a~onist of human platelets, The human platelets start to 
al~gregate at the concemration of thrombin around 0,03 
unirJrni [22] and m~ximal aggregation is obtained at 
the concentration of 0.S-l,0 -nit/ml, The inhibition of 
haman platclet aggregation and tyrosine phosphoryla- 
fion by prot¢iz~ kinas¢ inhibitor~ can only be s~n in the 
low concentration of thrombin, and in the prcscnc~ of" 
a higher concentration of' thrombin ([ unirJm[) neither 
tyrosine phosphorylation nor pl~telet aggregation is 
inhibited by these inhibi~ors. The reason why a higher 
conccmration of thrombin-induced aggregation was 
not inhibited by prot¢in-tyrosine kina,~ inhibitors is 
considered ~o be as follows. First, there are a lot o1" 
protein-tyrosin¢ kinases in human platelcts, so if :~ 
higher concentration of thrombin activates many pro- 
tein.tyrosine kinases, the inhibitors could not inhibit all 
the activity of protein-tyrosine kinases. Second, there 
are at least two different mechanisms of activation of 
platelets by thrombin: protein.tyrosin~ kiaas¢s are es- 
sential for the platclet activation in the case of lower 
concentration of thrombin but in the case of higher 
concentration of' thrombin phosphatidylinositol break- 
down seems to be directly activated [4]. Further studies 
are currently underway to understand the signal 
transdaction mechanism through protein-tyrosine 
phosphorylation in human platelet activation. 
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